公开(公告)号：USRE48825E1

公开(公告)日：2021-11-23

申请号：US16294607

申请日：2019-03-06

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： John Tomesch ,  Lawrence P. Wennogle

IPC: A61K31/4985 ,  C07D471/16 ,  C07D471/22 ,  C07D309/30 ,  C07C309/30

Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′: 4,5]pyrrolo[1,2,3 -de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and methods of using such crystals as 5-hydroxytryptamine 2 receptor agonists and antagonists in treating disorders of the central nervous system.

公开(公告)号：US09944648B2

公开(公告)日：2018-04-17

申请号：US15110613

申请日：2015-01-09

Applicant: Intra-Cellular Therapies, Inc.

Inventor： Qiang Zhang ,  Youyi Peng ,  Peng Li ,  J. David Beard ,  Lawrence P. Wennogle ,  John Tomesch

IPC: C07D487/04 ,  C07D235/30 ,  C07D277/82 ,  C07B59/00 ,  C07D401/12

CPC classification number: C07D487/04 ,  C07B59/002 ,  C07B2200/05 ,  C07D235/30 ,  C07D277/82 ,  C07D401/12

Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.

公开(公告)号：US09708294B2

公开(公告)日：2017-07-18

申请号：US14993048

申请日：2016-01-11

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Peng Li ,  Youyi Peng ,  John Tomesch ,  Lawrence P. Wennogle ,  Qiang Zhang

IPC: A61K31/445 ,  C07D401/12 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/506 ,  A61K33/24 ,  A61K45/06 ,  A61K31/41 ,  A61K31/415 ,  A61K31/7068

CPC classification number: C07D401/12 ,  A61K31/41 ,  A61K31/415 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.

公开(公告)号：US20170190703A9

公开(公告)日：2017-07-06

申请号：US15110613

申请日：2015-01-09

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Qiang Zhang ,  Youyi Peng ,  Peng Li ,  J. David Beard ,  Lawrence P. Wennogle ,  John Tomesch

IPC: C07D487/04 ,  C07D277/82 ,  C07D235/30 ,  C07B59/00 ,  C07D401/12

CPC classification number: C07D487/04 ,  C07B59/002 ,  C07B2200/05 ,  C07D235/30 ,  C07D277/82 ,  C07D401/12

Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.

公开(公告)号：US20160326179A1

公开(公告)日：2016-11-10

申请号：US15110613

申请日：2015-01-09

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Qiang Zhang ,  Youyi Peng ,  Peng Li ,  J. David Beard ,  Lawrence P. Wennogle ,  John Tomesch

IPC: C07D487/04 ,  C07D277/82 ,  C07D235/30 ,  C07B59/00 ,  C07D401/12

CPC classification number: C07D487/04 ,  C07B59/002 ,  C07B2200/05 ,  C07D235/30 ,  C07D277/82 ,  C07D401/12

Abstract: The invention provides novel compounds, composition comprising said compounds and methods for inhibiting CK1 as well as methods of treating CK1 related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 inhibitor to a patient in need thereof.

Abstract translation: 本发明提供新型化合物，包含所述化合物的组合物和用于抑制CK1的方法以及治疗CK1相关病症如阿尔茨海默氏病的方法，包括向有需要的患者施用治疗有效量的CK1抑制剂。